Source MDx Announces Partnership With Brigham and Women's Hospital to Study RNA-Based Biomarkers for Multiple Sclerosis

Published: Nov 03, 2008

BOULDER, Colo.--(BUSINESS WIRE)--Source MDx today announced a partnership with Brigham and Women’s Hospital in Boston to examine RNA-based biomarkers in multiple sclerosis (MS) patients and healthy control participants unaffected by the disease. The goal of the study is to identify diagnostic markers and to determine markers of active disease (relapses) or stable disease, along with response markers for currently available MS therapies. The study will utilize Source MDx’s patented gene expression profiling for the identification and monitoring of MS. The lead investigators for the study are Phil De Jager, M.D., Ph.D., Assistant Professor in the Department of Neurology at Brigham and Women’s Hospital and the Harvard Medical School/Partners Healthcare Center for Genetics & Genomics, and David Hafler, M.D., Director of Molecular Immunology at Brigham and Women’s Hospital and Professor of Neurology of Harvard Medical School.

Back to news